revenue
UCB presentation highlights impacts of epilepsy on daily life
The data underlines the consequences of disrupted sleep for patients and caregivers
UCB’s Kygevvi receives positive CHMP opinion for thymidine kinase 2 deficiency
TK2d is an extremely rare disease characterised by severe and progressive muscle weakness
UCB releases new data on Bimzelx for hidradenitis suppurativa
The disease affects around 1% of the population in most studied countries
UCB’s Fintepla shows positives results for Lennox-Gastaut syndrome
The study demonstrated a sustained reduction in seizures for patients
UCB shares promising results for fenfluramine in ultra-rare form of epilepsy
CDKL5 deficiency disorder occurs in approximately one in 40,000 to 60,000 live births
UCB’s Bimzelx demonstrates lasting efficacy in phase 3 psoriatic arthritis trials
Approximately 125 million people worldwide are affected by some form of psoriasis
UCB’s Bimzelx granted FDA approval to treat hidradenitis suppurativa in adults
The inflammatory skin disease affects approximately one in every 100 people in the US
UCB shares ‘encouraging’ data for Alzheimer’s disease candidate bepranemab
The drug showed benefits across key secondary endpoints, including tau accumulation
UCB shares positive two-year results for Bimzelx in hidradenitis suppurativa
The inflammatory skin disease affects about 1% of the population in most studied countries
UCB’s Bimzelx granted MHRA approval to treat hidradenitis suppurativa in adults
The authorisation applies to patients who have had an inadequate response to conventional systemic HS therapy
UCB shares positive phase 3 results for Zilbrysq in generalised myasthenia gravis
Zilbrysq is the first C5 inhibitor to show a clinically meaningful reduction of fatigue in the rare autoimmune disease
UCB’s Bimzelx granted EC approval to treat hidradenitis suppurativa in adults
The regulator’s decision marks Bimzelx’s fourth approved indication within the EU